首页> Respiratory medicine> Type 2 biomarkers outperform asthma-COPD overlap definitions in predicting clinical outcomes in COPD patients initiating triple therapy: A prospective cohort study.

Type 2 biomarkers outperform asthma-COPD overlap definitions in predicting clinical outcomes in COPD patients initiating triple therapy: A prospective cohort study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Hailun,Huang

第一单位： Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.

作者： Hailun,Huang ^[1] ; Huayuan,Liang ^[2] ; Junrao,Wang ^[3] ; Zhaoqian,Gong ^[1] ; Yuling,Hu ^[1] ; Guiling,Xu ^[1] ; Xueying,Zhao ^[1] ; Junwen,Huang ^[1] ; Yaoxin,Chen ^[1] ; Wenqu,Zhao ^[1] ; Haijin,Zhao ^[4]

作者单位： Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. ^[1] Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, 102218, China. ^[2] Department of Respiratory and Critical Care Medicine, Mianyang Central Hospital, Mianyang, 621099, China. ^[3] Chronic Airways Diseases Laboratory, Department of Respiratory and Critical Care Medicine, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China. Electronic address: zhjin@smu.edu.cn. ^[4]

关键词 ACO COPD Eosinophils FeNO Treatable traits Triple therapy Type 2 inflammation